Dose-adjusted EPOCH-Rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma.,Haematologica

当前位置： X-MOL 学术 › Haematologica › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Dose-adjusted EPOCH-Rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma.
Haematologica ( IF 8.2 ) Pub Date : 2021-09-09 , DOI: 10.3324/haematol.2021.278971
Fabian Knörr ₁ , Martin Zimmermann ₂ , Andishe Attarbaschi ₃ , Edita Kabíčková ₄ , Britta Maecker-Kolhoff ₂ , Stephanie Ruf ₅ , Ingrid Kühnle ₆ , Martin Ebinger ₇ , Anne-Kathrin Garthe ₈ , Ingrid Simonitsch-Klupp ₉ , Ilske Oschlies ₁₀ , Wolfram Klapper ₁₀ , Birgit Burkhardt ₈ , Wilhelm Woessmann ₁

Affiliation

UKE, Department of Pediatric Hematology and Oncology, Hamburg.
Hannover Medical School, Clinic for Pediatric Hematology and Oncology, Hannover.
St. Anna Children's Hospital, Medical University of Vienna, Department of Pediatric Hematology and Oncology, Vienna.
Charles University and University Hospital Motol, Department of Pediatric Hematology and Oncology, Prague, Czech Republic.
University of Gießen, Pediatric Hematology and Oncology, Gießen.
University Medical Center Göttingen, Division of Pediatric Hematology and Oncology, Göttingen.
Children's University Hospital Tübingen, Department of General Pediatrics and Pediatric Hematology/Oncology, Tübingen.
University-Hospital of Münster, Pediatric Hematology and Oncology, Münster.
Clinical Institute of Pathology, Medical University of Vienna, Vienna.
Universitätsklinikum Schleswig-Holstein, Campus Kiel, Institute of Pathology, Hematopathology Section and Lymph Node Registry, Kiel.